Posted on by admin

Spinal Cord Injury Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, NervGen Pharma

Spinal Cord Injury Market to Witness Upsurge in Growth During the Forecast Period (2024-2034), Examine DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, NervGen Pharma
The Spinal Cord Injury Market report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the 7MM.

DelveInsight’s “Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Spinal Cord Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Cord Injury Market Forecast

 

Some of the key facts of the Spinal Cord Injury Market Report: 

  • The Spinal Cord Injury market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In October 2023, NervGen Pharma has disclosed that the US Food and Drug Administration (FDA) has bestowed Fast Track designation upon its exclusive primary compound, NVG-291, for people affected by spinal cord injury.

  • As per the World Health Organization (WHO) in 2024, there are more than 15 million individuals worldwide living with spinal cord injuries.

  • According to Bennett et al. (2022), there are around 17,000 fresh incidents of spinal cord injury (SCI) reported annually in the United States, with an estimated 282,000 individuals living with SCI.

  • The projected number of identified cases of Spinal Cord Injury across the 7MM (Seven Major Markets) was roughly 725k cases in 2022, with an anticipated rise anticipated during the forecasted period from 2022 to 2032.

  • According to the National Spinal Cord Injury Statistical Center (NSCISC) (2024), the yearly occurrence rate of traumatic spinal cord injury (tSCI) stands at roughly 54 cases per one million individuals in the United States. This equates to approximately 18,000 new tSCI incidents annually.

  • The estimated number of diagnosed Spinal Cord Injury cases in the US in 2022 stood at approximately 326k with an anticipated rise projected during the forecasted period.

  • Key Spinal Cord Injury Companies: Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma, VA Office of Research and Development/Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc, AbbVie, and others

  • Key Spinal Cord Injury Therapies: KP-100IT, NEURO-CELLS, ABT-555 (elezanumab), MT-3921, AST-OPC1, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others

  • The Spinal Cord Injury epidemiology based on gender analyzed that Males are affected more as compared to females, in case of Spinal Cord Injury

  • The Spinal Cord Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinal Cord Injury pipeline products will significantly revolutionize the Spinal Cord Injury market dynamics.

 

Spinal Cord Injury Overview

A spinal cord injury (SCI) refers to damage to the spinal cord that results in a loss of function, sensation, or mobility. It can occur due to trauma, such as accidents or falls, or non-traumatic causes like infections or diseases. The severity of an SCI depends on factors such as the location and extent of the injury.

 

Get a Free sample for the Spinal Cord Injury Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/spinal-cord-injury-market

 

Spinal Cord Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Spinal Cord Injury Epidemiology Segmentation:

The Spinal Cord Injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Spinal Cord Injury

  • Prevalent Cases of Spinal Cord Injury by severity

  • Gender-specific Prevalence of Spinal Cord Injury

  • Diagnosed Cases of Episodic and Chronic Spinal Cord Injury

 

Download the report to understand which factors are driving Spinal Cord Injury epidemiology trends @ Spinal Cord Injury Epidemiology Forecast

 

Spinal Cord Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Spinal Cord Injury market or expected to get launched during the study period. The analysis covers Spinal Cord Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Spinal Cord Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Spinal Cord Injury Therapies and Key Companies

  • KP-100IT: Kringle Pharma

  • NEURO-CELLS: Neuroplast

  • ABT-555 (elezanumab): Abbvie

  • MT-3921: Mitsubishi Tanabe Pharma

  • AST-OPC1: Lineage Cell Therapeutics

  • NVG-291: NervGen Pharma

  • Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation

  • Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.

  • MT-3921: Mitsubishi Tanabe Pharma America Inc.

  • Elezanumab: AbbVie

 

Discover more about therapies set to grab major Spinal Cord Injury market share @ Spinal Cord Injury Treatment Landscape

 

Spinal Cord Injury Market Strengths

  • Both universities and industries are coming up with better approaches aiming towards development of a novel therapy

  • Advances in understanding of Spinal Cord Injury pathophysiology over recent years has however led to a surge of clinical trials

 

Spinal Cord Injury Market Opportunities

  • Recent continuous efforts in basic and clinical research are creating new path to regenerative medicine for Spinal Cord Injury

  • Absence of an effective therapy targeting symptoms and complications associated with Spinal Cord Injury

 

Scope of the Spinal Cord Injury Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Spinal Cord Injury Companies: Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma, VA Office of Research and Development/Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc, AbbVie, and others

  • Key Spinal Cord Injury Therapies: KP-100IT, NEURO-CELLS, ABT-555 (elezanumab), MT-3921, AST-OPC1, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others

  • Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies

  • Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Spinal Cord Injury Unmet Needs, KOL’s views, Analyst’s views, Spinal Cord Injury Market Access and Reimbursement 

 

To know more about Spinal Cord Injury companies working in the treatment market, visit @ Spinal Cord Injury Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Spinal Cord Injury Market Report Introduction

2. Executive Summary for Spinal Cord Injury

3. SWOT analysis of Spinal Cord Injury

4. Spinal Cord Injury Patient Share (%) Overview at a Glance

5. Spinal Cord Injury Market Overview at a Glance

6. Spinal Cord Injury Disease Background and Overview

7. Spinal Cord Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Spinal Cord Injury 

9. Spinal Cord Injury Current Treatment and Medical Practices

10. Spinal Cord Injury Unmet Needs

11. Spinal Cord Injury Emerging Therapies

12. Spinal Cord Injury Market Outlook

13. Country-Wise Spinal Cord Injury Market Analysis (2020–2034)

14. Spinal Cord Injury Market Access and Reimbursement of Therapies

15. Spinal Cord Injury Market Drivers

16. Spinal Cord Injury Market Barriers

17.  Spinal Cord Injury Appendix

18. Spinal Cord Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/